| P2093 | author name string | Jessy J Alexander | |
| | Richard J Quigg | |
| | Ravikumar Aalinkeel | |
| | Stanley A Schwartz | |
| | Supriya D Mahajan | |
| | Neil U Parikh | |
| | Kevin Le | |
| | Alexander Jacob | |
| | Katherine Cwiklinski | |
| | Alexander W Loftus | |
| | Prateet Sandhu | |
| P2860 | cites work | Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review | Q22242638 |
| | Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons | Q24537408 |
| | The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia | Q24650739 |
| | Guideline to reference gene selection for quantitative real-time PCR | Q28237161 |
| | The classical complement cascade mediates CNS synapse elimination | Q28261273 |
| | The good and evil of complement activation in HIV-1 infection | Q28275986 |
| | Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia | Q28571667 |
| | Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxins in vivo and in vitro | Q28583821 |
| | HIV-1 and hijacking of the host immune system: the current scenario | Q30248405 |
| | HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway | Q33628767 |
| | The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration | Q33685823 |
| | Complement components of the innate immune system in health and disease in the CNS. | Q33974402 |
| | Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. | Q34146463 |
| | Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia | Q34196506 |
| | Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells | Q34218827 |
| | Complement-dependent control of viral dynamics in pathogenesis of human immunodeficiency virus and simian immunodeficiency virus infection | Q34353051 |
| | Control of the complement system. | Q34400002 |
| | HIV and complement: hijacking an immune defense | Q34566493 |
| | Complement and HIV-I infection/HIV-associated neurocognitive disorders | Q34610122 |
| | Use of complement inhibitors in tissue injury | Q34838240 |
| | Cerebrospinal Fluid Proteomic Profiling of HIV-1-Infected Patients with Cognitive Impairment | Q56795823 |
| | Complement in different stages of HIV infection and pathogenesis | Q35124963 |
| | Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS | Q35165707 |
| | Role of mannose-binding lectin deficiency in HIV-1 and schistosoma infections in a rural adult population in Zimbabwe | Q35241916 |
| | Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells. | Q35677445 |
| | HIV-infection of the central nervous system: the tightrope walk of innate immunity | Q35920243 |
| | Impaired NK Cell Activation and Chemotaxis toward Dendritic Cells Exposed to Complement-Opsonized HIV-1. | Q35925669 |
| | Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells | Q35973601 |
| | HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment | Q36009246 |
| | Complement receptors | Q36166781 |
| | Clinical care of the HIV-infected drug user | Q36248580 |
| | Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells. | Q36313032 |
| | Mechanism(s) involved in opioid drug abuse modulation of HAND | Q36590733 |
| | Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections | Q36694953 |
| | HIV reservoirs and latency models. | Q36746403 |
| | Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. | Q37407370 |
| | Immunosuppressive effects of opioids--clinical relevance | Q37897497 |
| | Complement and blood-brain barrier integrity | Q38231669 |
| | μ-opioid modulation of HIV-1 coreceptor expressionand HIV-1 replication | Q38355088 |
| | Evolution of the complement system: from defense of the single cell to guardian of the intravascular space. | Q38991037 |
| | Complement: A primer for the coming therapeutic revolution | Q39028467 |
| | The Complement System in Neuropathic and Postoperative Pain | Q39116817 |
| | Complement Protein C1q Enhances Macrophage Foam Cell Survival and Efferocytosis. | Q39147404 |
| | Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy | Q39571037 |
| | Human immunodeficiency virus type 1 induces expression of complement factors in human astrocytes | Q39610112 |
| | Morphine induces defects in early response of alveolar macrophages to Streptococcus pneumoniae by modulating TLR9-NF-kappa B signaling | Q40010143 |
| | Regulation of complement component C3 in astrocytes by IL-1beta and morphine. | Q40017034 |
| | Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients | Q40175740 |
| | Morphine exacerbates HIV-1 viral protein gp120 induced modulation of chemokine gene expression in U373 astrocytoma cells | Q40397346 |
| | C5a alters blood-brain barrier integrity in a human in vitro model of systemic lupus erythematosus | Q40852487 |
| | A "complement-ary" AIDS vaccine | Q40953980 |
| | Establishment of human microglial cell lines after transfection of primary cultures of embryonic microglial cells with the SV40 large T antigen | Q41313592 |
| | HIV-1 induces complement factor C3 synthesis in astrocytes and neurons by modulation of promoter activity | Q42455611 |
| | Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis | Q42644285 |
| | Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection | Q45195944 |
| | Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease | Q45299150 |
| | Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction | Q45761035 |
| | Morphine modulates chemokine gene regulation in normal human astrocytes | Q46490212 |
| | DAMGO-induced expression of chemokines and chemokine receptors: the role of TGF-beta1. | Q46770172 |
| | Complement synthesis and activation in the brain of SIV-infected monkeys | Q47599450 |
| | Barriers to use of free antiretroviral therapy in injection drug users | Q50159275 |
| | Self-reported antiretroviral therapy in injection drug users. | Q53352327 |
| | C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells. | Q53662172 |
| P433 | issue | 8 | |
| P921 | main subject | opioid use disorder | Q1639178 |
| P304 | page(s) | 816-832 | |
| P577 | publication date | 2017-11-01 | |
| P1433 | published in | Immunological Investigations | Q15754982 |
| P1476 | title | Immunomodulatory Role of Complement Proteins in the Neuropathology Associated with Opiate Abuse and HIV-1 Co-Morbidity | |
| P478 | volume | 46 | |